Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carotegrast methyl - EA Pharma

Drug Profile

Carotegrast methyl - EA Pharma

Alternative Names: AJM 300

Latest Information Update: 04 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto
  • Developer EA Pharma
  • Class Anti-inflammatories; Quinazolines; Small molecules
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • No development reported Crohn's disease

Most Recent Events

  • 06 Jun 2018 EA Pharma initiates a phase III trial for Ulcerative colitis (In adolescents, In adults, In the elderly) in Japan (PO) (JapicCTI-183924)
  • 12 Apr 2018 EA Pharma plans a phase III trial for Ulcerative colitis (In adolescents, In adults, In the elderly) in Japan (PO) , (JapicCTI-183924)
  • 07 Sep 2017 Phase-III development for Ulcerative colitis is ongoing in Japan (PO) (EA Pharma pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top